NASDAQ:STOK Stoke Therapeutics (STOK) Stock Price, News & Analysis $14.70 -0.45 (-2.97%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$14.16▼$15.3150-Day Range$12.67▼$15.8652-Week Range$3.35▼$17.58Volume331,470 shsAverage Volume379,591 shsMarket Capitalization$773.96 millionP/E RatioN/ADividend YieldN/APrice Target$21.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Stoke Therapeutics alerts: Email Address Stoke Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside45.6% Upside$21.40 Price TargetShort InterestBearish18.78% of Shares Sold ShortDividend StrengthN/ASustainability-0.59Upright™ Environmental ScoreNews Sentiment0.19Based on 7 Articles This WeekInsider TradingSelling Shares$137,500 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.18) to ($2.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.10 out of 5 starsMedical Sector315th out of 910 stocksPharmaceutical Preparations Industry133rd out of 426 stocks 3.4 Analyst's Opinion Consensus RatingStoke Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageStoke Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Stoke Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted18.78% of the outstanding shares of Stoke Therapeutics have been sold short.Short Interest Ratio / Days to CoverStoke Therapeutics has a short interest ratio ("days to cover") of 15.2, which indicates bearish sentiment.Change versus previous monthShort interest in Stoke Therapeutics has recently increased by 0.71%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldStoke Therapeutics does not currently pay a dividend.Dividend GrowthStoke Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreStoke Therapeutics has received a 77.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Stoke Therapeutics is -0.59. Previous Next 1.8 News and Social Media Coverage News SentimentStoke Therapeutics has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Stoke Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for STOK on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $137,500.00 in company stock.Percentage Held by Insiders11.30% of the stock of Stoke Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Stoke Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.18) to ($2.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stoke Therapeutics is -6.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stoke Therapeutics is -6.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStoke Therapeutics has a P/B Ratio of 3.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Stoke Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About Stoke Therapeutics Stock (NASDAQ:STOK)Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.Read More STOK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STOK Stock News HeadlinesSeptember 7 at 4:25 AM | seekingalpha.comStoke Therapeutics: The First Gene Therapy For Dravet SyndromeSeptember 4 at 11:50 AM | finance.yahoo.comStoke Therapeutics to Present at Upcoming Investor Conferences in SeptemberSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …September 4 at 11:50 AM | finance.yahoo.comStoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business OfficerSeptember 3, 2024 | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of "Moderate Buy" by AnalystsSeptember 2, 2024 | uk.investing.comStoke Therapeutics Inc (STOK)August 28, 2024 | americanbankingnews.comEquities Analysts Offer Predictions for Stoke Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:STOK)August 16, 2024 | msn.comStoke sign Brighton midfielder Moran on loan dealSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …August 16, 2024 | msn.comHero of Stoke City's Premier League era returns 'home'August 15, 2024 | msn.comStoke City starlet Freddie Anderson on advice from dad Viv and Ryan Shawcross and that debut goalAugust 15, 2024 | msn.comStoke City close in on seventh signing of the summerAugust 15, 2024 | msn.comWatford boss makes Tom Ince prediction ahead of Stoke City reunionAugust 15, 2024 | yahoo.comStoke Space's initial launch plans at Cape Canaveral take shapeAugust 13, 2024 | msn.comPete Smith's Stoke City player ratings vs Carlisle as Freddie Anderson and Emre Tezgel find landmark goalsAugust 13, 2024 | msn.comStoke’s second-half double sees off CarlisleAugust 13, 2024 | msn.comStoke boss Steven Schumacher pleased to pass ‘difficult test’ at CarlisleAugust 13, 2024 | msn.comStoke sign Celtic's Lawal on four-year contractSee More Headlines Receive STOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:STOK CUSIPN/A CIK1623526 Webwww.stoketherapeutics.com Phone(781) 430-8200FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$21.40 High Stock Price Target$35.00 Low Stock Price Target$13.00 Potential Upside/Downside+45.6%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,700,000.00 Net Margins-683.35% Pretax Margin-683.35% Return on Equity-57.89% Return on Assets-42.22% Debt Debt-to-Equity RatioN/A Current Ratio6.67 Quick Ratio6.67 Sales & Book Value Annual Sales$8.78 million Price / Sales88.15 Cash FlowN/A Price / Cash FlowN/A Book Value$4.61 per share Price / Book3.19Miscellaneous Outstanding Shares52,650,000Free Float46,231,000Market Cap$773.96 million OptionableOptionable Beta0.96 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Edward M. Kaye M.D. (Age 75)Ph.D., CEO & Director Comp: $948.9kDr. Adrian R. Krainer Ph.D. (Age 65)Co-Founder & Independent Director Comp: $44kDr. Barry S. Ticho FACC (Age 63)M.D., Ph.D., Chief Medical Officer Comp: $684.55kMs. Isabel Aznarez Ph.D. (Age 51)Co-Founder & Group VP of Discovery Research Mr. Thomas Edward Leggett (Age 47)Chief Financial Officer Dr. Huw M. Nash Ph.D. (Age 57)COO & Chief Business Officer Comp: $429.67kMr. Eric RojasHead of Investor RelationsMr. Jonathan Allan J.D. (Age 34)Corporate Secretary & General Counsel Ms. Dawn Kalmar (Age 46)Chief Communications Officer Ms. Joan WoodChief Human Resources OfficerMore ExecutivesKey CompetitorsRevance TherapeuticsNASDAQ:RVNCArcturus TherapeuticsNASDAQ:ARCTHeron TherapeuticsNASDAQ:HRTXMersana TherapeuticsNASDAQ:MRSNShattuck LabsNASDAQ:STTKView All CompetitorsInsiders & InstitutionsGhisallo Capital Management LLCSold 15,000 shares on 9/4/2024Ownership: 0.028%Lynx1 Capital Management LPBought 1,488,371 shares on 8/15/2024Ownership: 9.848%Millennium Management LLCBought 243,083 shares on 8/15/2024Ownership: 0.549%The Manufacturers Life Insurance Company Bought 1,994 shares on 8/15/2024Ownership: 0.027%Profund Advisors LLCBought 14,893 shares on 8/14/2024Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions STOK Stock Analysis - Frequently Asked Questions How have STOK shares performed this year? Stoke Therapeutics' stock was trading at $5.26 at the beginning of 2024. Since then, STOK shares have increased by 179.5% and is now trading at $14.70. View the best growth stocks for 2024 here. How were Stoke Therapeutics' earnings last quarter? Stoke Therapeutics, Inc. (NASDAQ:STOK) posted its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.11. The company had revenue of $4.83 million for the quarter, compared to the consensus estimate of $3.33 million. Stoke Therapeutics had a negative net margin of 683.35% and a negative trailing twelve-month return on equity of 57.89%. When did Stoke Therapeutics IPO? Stoke Therapeutics (STOK) raised $100 million in an initial public offering (IPO) on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Stoke Therapeutics' major shareholders? Stoke Therapeutics' top institutional shareholders include Lynx1 Capital Management LP (9.85%), Assenagon Asset Management S.A. (2.82%), Marshall Wace LLP (2.21%) and Logos Global Management LP (1.99%). Insiders that own company stock include Skorpios Trust, Stephen J Tulipano, Jonathan Allan, Barry Ticho and Huw M Nash. View institutional ownership trends. How do I buy shares of Stoke Therapeutics? Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Stoke Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL) and Kaleido Biosciences (KLDO). This page (NASDAQ:STOK) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.